Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Study of Investigational Drugs in Moderate to Severe Hidradenitis Suppurativa
NCT03827798Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Bispecific Antibodies, Small Molecules
- Countries
- 11
01
Overview
Phase 2, randomised, double-blind trial of iscalimab, LYS006, MAS825, remibrutinib and ianalumab in hidradenitis suppurativa (HS) (11 cohorts), sponsored by Novartis. Primary endpoint: Simplified Hidradenitis Suppurativa Clinical Response at 16 weeks. Started Feb 2019; status: completed.
02
Drugs
iscalimabLYS006MAS825remibrutinibianalumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03827798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827798.